PMV Pharmaceuticals

Executive Summary

PMV Pharmaceuticals is a clinical-stage precision oncology company focused on developing small molecule therapies that reactivate mutant p53, the most common tumor suppressor mutation in cancer. Its lead candidate, rezatapopt (PC14586), is a first-in-class p53 reactivator targeting the Y220C mutation, currently in Phase 1/2 trials for advanced solid tumors. The company has a robust pipeline of additional p53-targeting candidates and is exploring combination strategies, including a Phase 1 trial with azacitidine in myelodysplastic syndrome/acute myeloid leukemia. Recent completed drug-drug interaction studies support the development of rezatapopt. As a publicly traded company, PMV Pharma represents a high-risk, high-reward opportunity in the targeted oncology space. The company's ability to demonstrate meaningful clinical benefit and advance toward registration will be critical to its valuation.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 efficacy data update for rezatapopt in p53 Y220C solid tumors60% success
• 2027Initiation of a pivotal trial for rezatapopt50% success
• H1 2027Interim data from the Phase 1 rezatapopt + azacitidine combination trial in MDS/AML40% success